Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial
Free-Photos / Pixabay

Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial

According to a story from globenewswire.com, the gene and cell therapy company Abeona Therapeutics Inc. recently announced that has received a letter from the US Food and Drug Administration (FDA)…

Continue Reading Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial

FDA Approval Was Granted For a Duchenne Muscular Dystrophy Drug Amid Internal Disagreements

  The accelerated approval granted by the FDA for the Duchenne muscular dystrophy drug eteplirsen, developed by Sarepta Therapeutics, was granted only after internal disagreements and protests had been resolved.…

Continue Reading FDA Approval Was Granted For a Duchenne Muscular Dystrophy Drug Amid Internal Disagreements

In Honor of Tay-Sachs Disease Awareness Month Organizations are Teaming Together to Spread Awareness of Genetic Testing

Tay-Sachs Disease September is Tay-Sachs Disease Awareness Month. Voted on by the Senate unanimously in 2008, this month aims to spread awareness about this disease and the importance of carrier…

Continue Reading In Honor of Tay-Sachs Disease Awareness Month Organizations are Teaming Together to Spread Awareness of Genetic Testing
After Visiting Nearly 100 Doctors, This Man Still Doesn’t Have a Diagnosis for His Rare Disease
Free-Photos / Pixabay

After Visiting Nearly 100 Doctors, This Man Still Doesn’t Have a Diagnosis for His Rare Disease

According to a story from the Washington Post, Bob Schwartz is a walking, talking medical mystery. He lives with a strange and diverse array of difficult symptoms, and after being…

Continue Reading After Visiting Nearly 100 Doctors, This Man Still Doesn’t Have a Diagnosis for His Rare Disease
Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension
Bokskapet / Pixabay

Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension

According to a story from Benzinga, the medical device company V-Wave Ltd. has recently announced that a product in development by the company has earned Breakthrough Device designation from the…

Continue Reading Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension
ICYMI: FDA Approves Expanded Access Application of Experimental Niemann-Pick Type C Drug
rawpixel / Pixabay

ICYMI: FDA Approves Expanded Access Application of Experimental Niemann-Pick Type C Drug

According to a press release from CTD Holdings, the American Food and Drug Administration (FDA) recently approved an Expanded Access application from a physician to treat a pediatric Niemann-Pick disease…

Continue Reading ICYMI: FDA Approves Expanded Access Application of Experimental Niemann-Pick Type C Drug
Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11
Source: Pixabay

Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11

According to a press release from global pharmaceuticals titan GlaxoSmithKline, the US Food and Drug Administration (FDA) recently expanded approval of the Company's eosinophilic asthma treatment Nucala (generic name mepolizumab)…

Continue Reading Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11
NHS Finally Reverses Almost 2 Year Policy Against Offering Cerliponase Alfa to Batten Disease Patients
source: pixabay.com

NHS Finally Reverses Almost 2 Year Policy Against Offering Cerliponase Alfa to Batten Disease Patients

According to a recent publication from Express Digest, England's National Health Service (NHS) has reversed its earlier position on a rare disease drug after lengthy public debate, now agreeing to…

Continue Reading NHS Finally Reverses Almost 2 Year Policy Against Offering Cerliponase Alfa to Batten Disease Patients
FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C
rawpixel / Pixabay

FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C

According to a story from ir.stockpr.com, the biotechnology company CTD Holdings, Inc., recently announced that the US Food and Drug Administration (FDA) has issued an approval for an individual Investigational…

Continue Reading FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C

FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma

  Diffuse large B-cell lymphoma  (DLBCL) is a common type of non-Hodgkins lymphoma. World Pharma News recently reported that the FDA approved the first chemoimmunotherapy, Polivy, for DLBCL in combination with…

Continue Reading FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma
The Drug Stelara Gains Approval for Moderate to Severe Ulcerative Colitis in the EU
pixel2013 / Pixabay

The Drug Stelara Gains Approval for Moderate to Severe Ulcerative Colitis in the EU

According to a story from BioSpace, Janssen Pharmaceutical Companies recently announced that the European Commission (EC) has expanded the approved indication of the company's drug ustekinumab (marketed as Stelara). This…

Continue Reading The Drug Stelara Gains Approval for Moderate to Severe Ulcerative Colitis in the EU
Grant From The American Neuromuscular Foundation Will Focus on Chronic Inflammatory Demyelinating Polyneuropathy
mwooten / Pixabay

Grant From The American Neuromuscular Foundation Will Focus on Chronic Inflammatory Demyelinating Polyneuropathy

According to a story from newswise.com, the American Neuromuscular Foundation has recently awarded a grant to Dr. Karissa Gable. This grant will go towards a research project headed by Dr.…

Continue Reading Grant From The American Neuromuscular Foundation Will Focus on Chronic Inflammatory Demyelinating Polyneuropathy

This Company Just Announced Plans to Develop a Gene Therapy for Type 2A Charcot-Marie-Tooth Disease

According to a story from BioSpace, the genetic medicines company Passage Bio recently announced plans for its sixth program for gene therapy development. The company plans to work with the…

Continue Reading This Company Just Announced Plans to Develop a Gene Therapy for Type 2A Charcot-Marie-Tooth Disease